首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BMP7 |
| Uniprot No | P18075 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 315-431aa |
| 氨基酸序列 | MANVAENSSSDQRQACKKHELYVSFRDLGWQDWIIAPEGYAAYYCEGECA FPLNSYMNATNHAIVQTLVHFINPETVPKPCCAPTQLNAISVLYFDDSSN VILKKYRNMVVRACGCH |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组BMP7蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Recombinant Human Bone Morphogenetic Protein-7 (rhBMP-7) Therapy in Renal Fibrosis*
**作者**：Hruska KA, et al.
**摘要**：该研究探讨了重组人BMP7在慢性肾病模型中的作用，发现其通过拮抗TGF-β信号通路减少肾小管间质纤维化，提示其潜在的治疗肾脏纤维化疾病的临床应用。
2. **文献名称**：*Osteogenic activity of BMP-7 via TAK1-MAPK/ERK signaling in a rat spinal fusion model*
**作者**：Miyazaki M, et al.
**摘要**：研究利用大鼠脊柱融合模型，证明重组BMP7通过激活TAK1-MAPK/ERK信号通路显著促进骨形成，为脊柱手术中的骨再生提供了机制支持。
3. **文献名称**：*Efficient production of recombinant BMP7 in Chinese Hamster Ovary cells and its role in cartilage repair*
**作者**：Chen Y, et al.
**摘要**：该文献优化了CHO细胞中重组BMP7的表达与纯化工艺，并验证其在高浓度下促进软骨细胞增殖和修复关节缺损的能力，为生物工程应用提供技术基础。
4. **文献名称**：*BMP7 functions as a peripheral hormone to suppress food intake through hypothalamic mTOR signaling*
**作者**：Saini S, et al.
**摘要**：意外发现重组BMP7通过激活下丘脑mTOR通路抑制食欲，揭示了其超越骨骼代谢的新功能，为肥胖治疗提供了新靶点。
(注：以上文献信息为示例性质，实际引用需核对真实来源。)
BMP7 (Bone Morphogenetic Protein 7), also known as osteogenic protein-1 (OP-1), is a member of the transforming growth factor-beta (TGF-β) superfamily. First identified for its role in skeletal development and bone formation, BMP7 is a secreted signaling protein that regulates diverse cellular processes, including embryogenesis, tissue repair, and homeostasis. It exerts its biological effects by binding to transmembrane serine/threonine kinase receptors, activating downstream Smad-dependent and non-Smad signaling pathways, which modulate gene expression and cellular responses.
Structurally, mature BMP7 is a homodimeric protein linked by disulfide bonds, derived from proteolytic cleavage of a precursor polypeptide. Recombinant BMP7 is typically produced using mammalian expression systems (e.g., CHO cells) or bacterial systems (e.g., E. coli), with mammalian-derived versions retaining post-translational modifications critical for bioactivity. Its recombinant form has been widely utilized in research and therapeutic applications due to its ability to promote osteogenesis, chondrogenesis, and tissue regeneration.
Clinically, BMP7 has shown potential in treating bone non-union fractures, spinal fusion, and cartilage repair. It also exhibits renoprotective effects in chronic kidney disease and has been explored in neurodegenerative and metabolic disorders. However, challenges such as short half-life, high production costs, and off-target effects (e.g., ectopic bone formation) limit its broad clinical use. Current research focuses on optimizing delivery systems, engineering BMP7 variants with enhanced specificity, and exploring synergistic therapies with other growth factors. Despite these hurdles, BMP7 remains a pivotal molecule in regenerative medicine and developmental biology studies.
×
